2 completed, 2 terminated, 1 unknown. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Terminated 2, Completed 1 |
Follow Claudio Gobbi: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy Cladribine Oral Tablet, Rituximab, Ocrelizumab - Multiple Sclerosis | Unknown | Claudio Gobbi | 45 | 2020-12-17 | 2022-03-23 | |
| Multidimensional Assessment of Fatigue in Multiple Sclerosis- Observational Study - Ticino Multiple Sclerosis | Completed | Claudio Gobbi | 93 | 2013-11-01 | 2019-03-21 | |
| Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis Interferon beta-1b - Relapsing-remitting Multiple Sclerosis | Phase 4 | Terminated | Claudio Gobbi | 5 | 2012-09-01 | 2014-01-22 |
| Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis Prednisone, Placebo - Multiple Sclerosis | Phase 4 | Terminated | Claudio Gobbi | 27 | 2011-08-01 | 2015-12-18 |
| Natalizumab De-escalation With Interferon Beta-1b interferon beta-1b, Natalizumab - Relapsing-remitting Multiple Sclerosis | Phase 4 | Completed | Claudio Gobbi | 19 | 2010-06-01 | 2014-04-17 |
Multiple Sclerosis (3) · Multiple Sclerosis, Relapsing-Remitting (2) · Cognitive Dysfunction (1) · Depression (1) · Fatigue (1) · Multiple Sclerosis, Chronic Progressive (1) · Sleepiness (1)
Interferon beta-1b (2) · Cladribine (1) · Natalizumab (1) · Prednisone (1) · Rituximab (1) · ocrelizumab (1)
Switzerland (5)